Meisha Smith
Primary Care · Spring, TXNPI 1740728005
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,918 and has fallen 96.6% since, to $66 in 2024. Among primary care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$588
- Amgen$515
- Daiichi Sankyo Inc.$503
- AstraZeneca$473
- Johnson & Johnson$419
- Boehringer Ingelheim$392
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,646100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 36 | $588 |
| Amgen | 34 | $515 |
| Daiichi Sankyo Inc. | 8 | $503 |
| AstraZeneca | 15 | $473 |
| Johnson & Johnson | 18 | $419 |
| Boehringer Ingelheim | 10 | $392 |
| E.r. Squibb & Sons, L.L.C. | 20 | $365 |
| Abbott | 2 | $219 |
| Novo Nordisk | 9 | $199 |
| Novartis | 11 | $199 |
| Merck | 10 | $175 |
| Sanofi-aventis U.S. LLC | 7 | $105 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $99 |
| Pfizer | 3 | $66 |
| Amarin Pharma, Inc. | 3 | $62 |
| Lilly USA, LLC | 3 | $48 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $38 |
| Edwards Lifesciences | 1 | $30 |
| Cvrx, Inc. | 1 | $24 |
| GSK | 1 | $19 |
| Medicomp Inc | 1 | $19 |
| Medtronic | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INJECTAFER$412
- FARXIGA$248
- JARDIANCE$247
- Repatha$125
- NEXLIZET$125
- NEXLETOL$125
- CARDIOMEMS$123
- XARELTO$112
How this compares
$4,646 in reported general payments places this provider in the 95th percentile of 563 primary care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $8,097 |
| FarxigaDapagliflozin Propanediol | 11 | $4,835 |
| Midodrine Hcl | 14 | $886 |
| Sucralfate | 12 | $281 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $158 |
| Pantoprazole Sodium | 30 | $118 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $115 |
| Gabapentin | 17 | $93 |
| Atorvastatin Calcium | 26 | $68 |
| Metoprolol Succinate | 21 | $61 |
| Spironolactone | 28 | $49 |
| Furosemide | 27 | $42 |
| Carvedilol | 15 | $39 |
| ClopidogrelClopidogrel Bisulfate | 12 | $36 |
| Amlodipine Besylate | 19 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $66 | $8,09717 claims |
| AstraZenecaFarxiga | $473 | $4,83511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 563 primary care providers in Texas.
Other primary care in Spring
- Mary GibbensHouston$42K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
- Arlena GraysTomball$9K
- Charlotte BallardSan Antonio$9K
- Hannah LancasterMcKinney$9K
- Jacqueline MilesGrand Prairie$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.